News

Investigators ranked ChatGPT responses to healthcare professional-oriented questions about IBD as more useful and reliable than the model’s responses to patient-oriented questions.

For This Year in Medicine, CGTLive looks back at a landmark first approval, the new treatment opportunities it has provided, and the unmet needs in the field it has brought to light.

Lungcast is joined by an environmental engineer to discuss the burden of harmful air in US school systems today.

Our November 2023 hepatology month in review spotlights data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases (AASLD) as well as news about hepatitis B and C.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our November 2023 month-in-review features a trio of FDA news, important updates to the GA pipeline, and insight into disparities in eye care.

These new data highlight key points about the timeline of benefits for those who quit smoking cigarettes, including respiratory and cardiovascular benefits.

Our November 2023 month in review for cardiology features highlights from AHA 2023, new atrial fibrillation guidelines, a pair of historic approvals from the FDA, and more!

Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab.

Higher vitamin B1 intake levels were associated with lower prevalence of late AMD in an analysis of NHANES data from 2005 to 2008.

A treat-and-extend regimen with aflibercept showed both anatomical and functional improvements for patients with nAMD and PCV during a two-year study.

In this retrospective review of medical charts, trends in systemic treatment use among psoriasis patients in Japan pointed to several notable findings.

Russell D Cohen, MD, explains how biosimilars represent an opportunity to expand access and reduce the financial burden of high-cost biologics.

A meta-analysis of trials examining use of preoperative iron infusions suggests use could reduce need for blood transfusions by 33% among patients undergoing colorectal surgery.

November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors.

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

This new data adds to the growing body of literature regarding the benefits and risks of prescribing isotretinoin for dermatology patients.

Metformin use was associated with a reduced likelihood of any AMD and dry AMD in a sample of patients without diabetes.

In this interview with Dr. Eichenfield, comparisons between ruxolitinib and other treatments for eczema were discussed.

Released on Nov. 30, 2023, the new AFib guidance from the ACC/AHA contains update recommendations for early and aggressive rhythm control, wearables, left atrial appendage occlusion, and more.

8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.

This discussion with Dr. Eichenfield featured coverage of data on ruxolitinib for eczema patients.

Pretreatment vitamin D levels were associated with endoscopic improvement in patients with UC and decreased C-reactive protein levels in patients with CD.

Ophthalmology registry data show increased macular fluid volume after initial treatment are associated with increased numbers of injections in nAMD treatment.

Factors associated with receiving eye care in past 12 months included a higher educational level and income, while food and housing insecurity were associated with not receiving eye care.

A trial randomizing brain-dead donor hearts to levothyroxine administration or saline has returned results challenging conventional wisdom on the topic, with data indicating thyroid hormone administration may provide no significant benefit.

A qualitative study in Denmark explores the adherence of patients with nAMD to their treatment regimen despite various barriers, including access to care and poor health literacy.

This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.